Merck is rated Sell with a $123.00 price target. At 16.2 times 2027 earnings, the market overlooks a severe patent cliff where Keytruda generates 50% of revenue ahead of 2028 exclusivity expiration and 2029 Medicare price setting.
Key points
- 49.9% of first-half 2026 sales came from Keytruda, creating an unavoidable earnings cliff when its compound patent expires in December 2028.
- $142.82 per share values Merck at 16.2 times 2027 underlying earnings, pricing an unrealistically smooth handoff to subcutaneous and pipeline assets.
- $45.5 billion in net debt limits further large-scale M&A after absorbing $16.0 billion across the Cidara and Terns transactions.
The call
The current price requires investors to pay 16.2 times forward earnings for a business facing generic and regulatory erosion across half its revenue within twenty-six months. Market enthusiasm over pipeline headlines has driven a 63% twelve-month rally, assuming new launches seamlessly replace Keytruda cash flows without multiple compression.
Quarterly revenue ($ billions)- Reported Revenue
- Forecast Revenue
Reported quarterly revenue and free cash flow through Q2 2026; Q3 2026E to Q4 2027E are analyst forecasts.
Instead, valuation must derate to 14.0 times 2027 earnings as the December 2028 patent expiration approaches. Generic Januvia and Bridion are already eroding roughly $4.0 billion in high-margin legacy sales. CMS price-setting risks for Keytruda in January 2029 will cap terminal cash flows well before pipeline candidates achieve offsetting scale.
Valuation
| Driver and valuation bridge | Value |
|---|
| FY26 guided revenue (midpoint) | $66.8 billion |
| FY27 forecast revenue (+3.0% growth) | $68.8 billion |
| FY27 normalized operating margin | 39.6% |
| FY27 forecast diluted shares | 2.46 billion |
| FY27 forecast normalized EPS | $8.80 |
| Target forward P/E multiple | 14.0 times |
| 12-month price target | $123.00 |
A 14.0 times multiple reflects historical big-pharma deratings ahead of flagship loss-of-exclusivity transitions. The 13.9% downside offers poor risk asymmetry, supporting a Sell rating.
Risks
- Accelerated uptake of subcutaneous Keytruda Qlex: observe whether conversion crosses 50% in major outpatient oncology centers.
- Winrevair outperformance: watch quarterly U.S. patient additions for persistent acceleration above 2,000 new prescriptions.
- Regulatory exemption under the Inflation Reduction Act: monitor CMS draft negotiation guidance for distinct biological classification of fixed combinations.
What would change my mind
A binding CMS rule fully exempting Keytruda Qlex from Medicare price negotiation through 2032 would eliminate the near-term earnings cliff.